SMART
2006
Salmeterol Multicenter Asthma Research Trial
In 26,355 patients with asthma, salmeterol added to usual care increased respiratory-related and asthma-related mortality compared with placebo plus usual care.
Result
Efficacy: Respiratory- and asthma-related death/life-threatening eventRR 2.16
Below 1 favours salmeterol added to usual care, above 1 favours placebo plus usual care.
Event rates Salmeterol added to usual care 24 vs placebo plus usual care 11 events
Also reported: Asthma deaths 13 vs 3. Excess concentrated in African-Americans and ICS-naïve patients.
- Subtopic
- LABA safety
- Design
- Multicentre RCT, USA
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Nelson HS, et al. Chest. 2006;129(1):15-26.doi 10.1378/chest.129.1.15
Discussion & critique
Triggered the FDA LABA black-box warning and the modern rule that LABAs must be combined with ICS in asthma.